JP2010501479A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010501479A5 JP2010501479A5 JP2009524014A JP2009524014A JP2010501479A5 JP 2010501479 A5 JP2010501479 A5 JP 2010501479A5 JP 2009524014 A JP2009524014 A JP 2009524014A JP 2009524014 A JP2009524014 A JP 2009524014A JP 2010501479 A5 JP2010501479 A5 JP 2010501479A5
- Authority
- JP
- Japan
- Prior art keywords
- arg
- amino acid
- shows
- amino acids
- independently selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001413 amino acids Chemical group 0.000 description 60
- 229940024606 amino acid Drugs 0.000 description 48
- 235000001014 amino acid Nutrition 0.000 description 48
- 150000001875 compounds Chemical class 0.000 description 11
- 238000000034 method Methods 0.000 description 9
- ZAVGJDAFCZAWSZ-UHFFFAOYSA-N hydroxyfasudil Chemical compound C1=CC=C2C(O)=NC=CC2=C1S(=O)(=O)N1CCCNCC1 ZAVGJDAFCZAWSZ-UHFFFAOYSA-N 0.000 description 7
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 239000004471 Glycine Substances 0.000 description 6
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical group C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 6
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical group CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 6
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical group CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 6
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 6
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical group CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 6
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Chemical group CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 6
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 6
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 6
- 239000004473 Threonine Substances 0.000 description 6
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical group CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 6
- 235000004279 alanine Nutrition 0.000 description 6
- NGOGFTYYXHNFQH-UHFFFAOYSA-N fasudil Chemical compound C=1C=CC2=CN=CC=C2C=1S(=O)(=O)N1CCCNCC1 NGOGFTYYXHNFQH-UHFFFAOYSA-N 0.000 description 6
- 229960002435 fasudil Drugs 0.000 description 6
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 6
- 229960000310 isoleucine Drugs 0.000 description 6
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 6
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 6
- 229930182817 methionine Chemical group 0.000 description 6
- 239000004474 valine Chemical group 0.000 description 6
- 230000015654 memory Effects 0.000 description 5
- 230000003936 working memory Effects 0.000 description 5
- 238000012347 Morris Water Maze Methods 0.000 description 4
- 102100022309 Protein KIBRA Human genes 0.000 description 4
- 101710145046 Protein kibra Proteins 0.000 description 4
- 241000700159 Rattus Species 0.000 description 3
- 210000001320 hippocampus Anatomy 0.000 description 3
- AKJHMTWEGVYYSE-AIRMAKDCSA-N 4-HPR Chemical compound C=1C=C(O)C=CC=1NC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C AKJHMTWEGVYYSE-AIRMAKDCSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 229950003662 fenretinide Drugs 0.000 description 2
- 238000002599 functional magnetic resonance imaging Methods 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- AWDORCFLUJZUQS-ZDUSSCGKSA-N (S)-2-methyl-1-(4-methylisoquinoline-5-sulfonyl)-1,4-diazepane Chemical compound C[C@H]1CNCCCN1S(=O)(=O)C1=CC=CC2=CN=CC(C)=C12 AWDORCFLUJZUQS-ZDUSSCGKSA-N 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical class CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- IYOZTVGMEWJPKR-IJLUTSLNSA-N Y-27632 Chemical compound C1C[C@@H]([C@H](N)C)CC[C@@H]1C(=O)NC1=CC=NC=C1 IYOZTVGMEWJPKR-IJLUTSLNSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 102000054766 genetic haplotypes Human genes 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 210000003478 temporal lobe Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83703006P | 2006-08-10 | 2006-08-10 | |
| US91747607P | 2007-05-11 | 2007-05-11 | |
| PCT/US2007/075728 WO2008019395A2 (en) | 2006-08-10 | 2007-08-10 | Compounds for improving learning and memory |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010501479A JP2010501479A (ja) | 2010-01-21 |
| JP2010501479A5 true JP2010501479A5 (enExample) | 2010-07-01 |
Family
ID=39033625
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009524014A Pending JP2010501479A (ja) | 2006-08-10 | 2007-08-10 | 学習および記憶を改善するための化合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20080108568A1 (enExample) |
| EP (1) | EP2061314A4 (enExample) |
| JP (1) | JP2010501479A (enExample) |
| AU (1) | AU2007281701A1 (enExample) |
| CA (1) | CA2659289A1 (enExample) |
| WO (1) | WO2008019395A2 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5191906B2 (ja) * | 2006-01-27 | 2013-05-08 | トランスレーショナル ジェノミクス リサーチ インスティテュート | ヒトの記憶性能に影響を及ぼす遺伝子 |
| CA2725416A1 (en) * | 2008-05-12 | 2009-11-19 | Amnestix, Inc. | Compounds for improving learning and memory |
| US9072730B2 (en) * | 2009-05-14 | 2015-07-07 | The Board Of Trustees Of The Leland Stanford Junior University | Method of improving cognitive functions in individuals with down syndrome and/or alzheimer's disease |
| EP2354789A1 (en) * | 2010-02-08 | 2011-08-10 | Sygnis Bioscience GmbH & Co. KG | Method for the identification of memory modulating compounds by assessing KIBRA expression |
| US20120010196A1 (en) * | 2010-04-02 | 2012-01-12 | Qin Quingyu | Methods of treating neurodegenerative disorders and diseases |
| WO2012006640A2 (en) * | 2010-07-09 | 2012-01-12 | Translational Genomics Research Institute | Compositions and methods useful in enhancement of memory |
| WO2013041238A1 (en) * | 2011-09-21 | 2013-03-28 | Sygnis Bioscience Gmbh & Co. Kg | Use of kibra peptides, hdac inhibitor or proteasome inhibitor for improving anxiety disorders |
| KR102276424B1 (ko) | 2014-10-06 | 2021-07-12 | 삼성전자주식회사 | 로-키나제 저해제를 포함하는 세포의 노화를 감소시키기 위한 조성물 및 그의 용도 |
| US10238870B2 (en) | 2015-10-27 | 2019-03-26 | Hrl Laboratories, Llc | Transcranial control of procedural memory reconsolidation for skill acquisition |
| US11587644B2 (en) | 2017-07-28 | 2023-02-21 | The Translational Genomics Research Institute | Methods of profiling mass spectral data using neural networks |
| US11666583B2 (en) | 2020-01-09 | 2023-06-06 | Woolsey Pharmaceuticals, Inc. | Methods of treating cortical dementia associated wandering |
| EP4125879A4 (en) | 2020-03-25 | 2024-04-03 | Woolsey Pharmaceuticals, Inc. | METHODS OF TREATMENT OF SPATIO-TEMPORAL DISORIENTATION ASSOCIATED WITH PROTEINOPATHY |
| WO2021216139A1 (en) * | 2020-04-23 | 2021-10-28 | Woolsey Pharmaceuticals, Inc | Methods of using rho kinase inhibitors to treat alzheimer's disease |
| CN116249532A (zh) * | 2020-06-15 | 2023-06-09 | 乌尔塞制药公司 | 使用Rho激酶抑制剂治疗血管性痴呆的方法 |
| CA3184122A1 (en) * | 2020-07-14 | 2022-01-20 | Thomas Macallister | Methods of treating proteinopathies |
| CN112010805B (zh) * | 2020-08-26 | 2023-12-05 | 山东威高药业股份有限公司 | 一种盐酸法舒地尔的精制方法 |
| US20230321114A1 (en) * | 2020-08-27 | 2023-10-12 | Woolsey Pharmaceuticals, Inc. | Methods of treating age-related cognitive decline |
| MX2023002396A (es) * | 2020-08-28 | 2023-05-10 | Woolsey Pharmaceuticals Inc | Métodos para tratar el deterioro cognitivo relacionado con la edad. |
| WO2022086581A1 (en) | 2020-10-22 | 2022-04-28 | Woolsey Pharmaceuticals, Inc | Methods of treating 4-repeat tauopathies |
| WO2023097151A1 (en) | 2021-11-29 | 2023-06-01 | Woolsey Pharmaceuticals, Inc. | Methods of treating agitation and other dementia-associated behavioral symptoms |
| CN114457154B (zh) * | 2022-04-13 | 2022-06-28 | 山东第一医科大学附属省立医院(山东省立医院) | KIBRA rs17070145检测试剂在制备嗅觉功能评价试剂盒中的应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5993054A (ja) * | 1982-11-18 | 1984-05-29 | Asahi Chem Ind Co Ltd | イソキノリンスルホン酸アミド誘導体 |
| US4678783B1 (en) * | 1983-11-04 | 1995-04-04 | Asahi Chemical Ind | Substituted isoquinolinesulfonyl compounds |
| JPH0667926B2 (ja) * | 1985-11-12 | 1994-08-31 | 旭化成工業株式会社 | 環状のイソキノリンスルホンアミド誘導体 |
| US5385915A (en) * | 1990-05-16 | 1995-01-31 | The Rockefeller University | Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation |
| JP3464012B2 (ja) * | 1993-04-05 | 2003-11-05 | 旭化成株式会社 | 精神症候治療剤 |
| ES2142065T3 (es) * | 1995-07-03 | 2000-04-01 | Asahi Chemical Ind | Clorhidratos de 1-(5-isoquinoleinsulfonil)homopiperazina hidratado. |
| WO2000009133A1 (fr) * | 1998-08-10 | 2000-02-24 | Asahi Kasei Kogyo Kabushiki Kaisha | Preparations orales, a liberation prolongee, a base de chlorhydrate de fasudil |
| US7655423B2 (en) * | 1999-06-14 | 2010-02-02 | Henry Ford Health System | Nitric oxide donors for inducing neurogenesis |
| US20020173535A1 (en) * | 2001-02-07 | 2002-11-21 | Renshaw Perry F. | Cholesterol-lowering agents as treatment for psychological and cognitive disorders |
| AU2002305269B2 (en) * | 2001-04-27 | 2006-10-19 | Cold Spring Harbor Laboratory | Alleviation of the memory deficits and memory components of psychiatric dysfunctions by altering atypical PKM activity |
| DE10153605A1 (de) * | 2001-11-02 | 2003-05-28 | Morphochem Ag Komb Chemie | Verwendung von Inhibitoren der Rho-Kinasen zur Stimulation des Nervenwachstums, zur Inhibition der Narbengewebsbildung und/oder Reduktion eines Sekundärschadens |
| WO2004106325A1 (en) * | 2003-05-29 | 2004-12-09 | Schering Aktiengesellschaft | Prodrugs of 1-(1-hydroxy-5-isoquinolinesulfonyl)homopiperazine |
| WO2005117896A1 (de) * | 2004-06-03 | 2005-12-15 | Schering Aktiengesellschaft | Formulierungen, die fasudil, eine matrix und einem mantel enthalten |
| JP5191906B2 (ja) * | 2006-01-27 | 2013-05-08 | トランスレーショナル ジェノミクス リサーチ インスティテュート | ヒトの記憶性能に影響を及ぼす遺伝子 |
| US7858611B2 (en) * | 2006-05-09 | 2010-12-28 | Braincells Inc. | Neurogenesis by modulating angiotensin |
-
2007
- 2007-08-10 CA CA002659289A patent/CA2659289A1/en not_active Abandoned
- 2007-08-10 US US11/837,326 patent/US20080108568A1/en not_active Abandoned
- 2007-08-10 WO PCT/US2007/075728 patent/WO2008019395A2/en not_active Ceased
- 2007-08-10 AU AU2007281701A patent/AU2007281701A1/en not_active Abandoned
- 2007-08-10 EP EP07840881A patent/EP2061314A4/en not_active Withdrawn
- 2007-08-10 JP JP2009524014A patent/JP2010501479A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010501479A5 (enExample) | ||
| CA2923685C (en) | Application of r-ketamine and salt thereof as pharmaceuticals | |
| US8088951B2 (en) | Epigenetic mechanisms re-establish access to long-term memory after neuronal loss | |
| US20220117967A1 (en) | Compositions and Methods for the Treatment of Prader-Willi Syndrome | |
| US9402826B2 (en) | Neuronal pain pathway modulators | |
| US20120295853A1 (en) | Neuronal pain pathway | |
| CN109475539B (zh) | 帕金森氏病的治疗 | |
| US10676747B2 (en) | Methods for improving cognitive function via modulation of quinone reductase 2 | |
| JP2012508249A5 (enExample) | ||
| US11060144B2 (en) | Prediction of sleep parameter and response to sleep-inducing compound based on PER3 VNTR genotype | |
| JP2015535247A5 (enExample) | ||
| JPWO2016129583A1 (ja) | 乳酸脱水素酵素阻害剤およびそれを含有する抗てんかん剤 | |
| JP2023088996A (ja) | 癌治療 | |
| JP2007527859A (ja) | グリコーゲンシンターゼキナーゼ−３阻害剤 | |
| Zhang et al. | Sphingosine‐1‐phosphate related signalling pathways manipulating virus replication | |
| KR20210073743A (ko) | 벤즈히드릴 티오 아세트아미드 화합물을 유효성분으로 포함하는 섬유화 질환의 치료용 조성물 | |
| RU2011101771A (ru) | Педиатрические композиции для лечения рассеянного склероза | |
| US20060167026A1 (en) | Antipsychotic molecular-targeting epithelial growth factor receptor | |
| Samarska et al. | S1P1 receptor modulation preserves vascular function in mesenteric and coronary arteries after CPB in the rat independent of depletion of lymphocytes | |
| KR102465000B1 (ko) | 다발성 골수종 치료 | |
| PT1926483E (pt) | Tratamento de doenças autoimunes | |
| JP2024543963A (ja) | 高い安定性及び遺伝子サイレンシング活性を有する低分子干渉ｒｎａ分子のための修飾パターン | |
| JP4954888B2 (ja) | グリコーゲンシンターゼキナーゼ−３阻害剤 | |
| Perveen et al. | Charcot-Marie-Tooth type 1A disease from patient to laboratory | |
| CN110693886B (zh) | 防治脑海绵状血管畸形病变的药物 |